Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) may cut the risk of obesity-related cancer (ORC) in patients being treated for diabetes and obesity.

Glucagon-like peptide-1 receptor agonists may cut the risk of obesity-related cancer in patients being treated for diabetes and obesity.

Novo Nordisk NVO and Viking Therapeutics VKTX have emerged as notable players in the obesity space. A market leader in the ...

“This study offers compelling early evidence that GLP-1 receptor agonists [GLP-1 RA] may help delay or even ... then used propensity matching to compare the 5719 patients who received a GLP ...

In clinical trials, semaglutide proved to be superior to placebo, with weight loss reaching 15%, suggesting its superiority over other non-GLP-1 RA anti ... undertreated in comparison to its ...

A systematic review and meta-analysis published in JAMA Psychiatry found little evidence of increased suicidality among glucagon-like peptide 1 receptor agonist (GLP-1 RA) recipients in ... as ...

In clinical trials, semaglutide proved to be superior to placebo, with weight loss reaching 15%, suggesting its superiority over other non-GLP-1 RA anti-obesity medications ... still significantly ...

Observational data suggest that sodium-glucose cotransporter-2 inhibitor (SGLT2i) and glucagon-like peptide-1 receptor agonist (GLP-1RA ... of heterogeneity between comparison interventions.

Annual prevalence of GLP-1 RA use among US adults without diabetes increased from 0.1% in 2018-2021 to 0.4% in 2022, with an estimated 854,728 adults without diabetes taking these medications.

Get Instant Summarized Text (Gist) GLP-1 receptor agonists are safe and effective for weight loss and glycemic control in adults with severe mental illness, including those on psychotropic medications ...